Rock Creek Pharmaceuticals Appoints New Director

Nov 19, 2015, 08:40 ET from Rock Creek Pharmaceuticals, Inc.

SARASOTA, Fla., Nov. 19, 2015 /PRNewswire/ -- Rock Creek Pharmaceuticals, Inc., (OTCQB: RCPI), a clinical stage drug development company focused on the application of its lead compound being developed to treat chronic inflammatory conditions, announced today that the Company has made a key independent appointment to the Company's Board of Directors with the recent election of Mr. Robert Scannell (Age 57), as a new director, bringing the number of directors to five.

Michael Mullan, MBBS, PhD, Chairman and CEO of Rock Creek Pharmaceuticals, said, "I am delighted that Bob is joining our Company as we advance through formal drug development. Bob's experience, judgment and overall investment acumen, coupled with his long term support of the Company, will be extremely helpful as we work to expand our industry profile and corporate development."

Mr. Scannell is a professional private equity investor, portfolio manager and investment management firm founder. He is the Co-Founder and General Partner of IASO Advisors, LLC, an investment firm focused on healthcare and biotech. Prior to IASO Advisors, Mr. Scannell was Founder and General Partner of Tradewinds Investment Management, accumulating a 20-year record of success and $400 million of assets. Mr. Scannell began his financial career working with corporate and convertible bonds, high yield and emerging market debt at Merrill Lynch Capital Markets. Mr. Scannell has a Juris Doctorate from Concord Law School, Los Angeles, CA., an MBA in Finance and a BA in Speech and Journalism, both from Penn State University. Mr. Scannell is a Chartered Financial Analyst (CFA).

About Anatabine Citrate:

Rock Creek Pharmaceuticals' compound is a small molecule, cholinergic agonist that exhibits anti-inflammatory pharmacological characteristics, distinct from other anti-inflammatory drugs available such as biologics, steroids and non-steroidal anti-inflammatories. The Company's lead compound has been investigated extensively in pre-clinical (in vitro and in vivo) studies resulting in several peer reviewed and published scientific journal articles, covering models of multiple sclerosis, Alzheimer's disease, and autoimmune thyroiditis. All these studies demonstrated the anti-inflammatory effects of the Company's compound. In addition, the Company's compilation of human exposure, safety and tolerability data, has provided important insights for ongoing clinical and regulatory pharmaceutical development.

About Rock Creek Pharmaceuticals, Inc.:

Rock Creek Pharmaceuticals, Inc. is an emerging drug development company focused on the discovery, development and commercialization of new drugs, formulations and compounds that provide therapies for chronic and acute inflammatory diseases.

For more information, visit:  

Forward Looking Statements:

Certain statements contained in this release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to statements identified by words such as "believes," "expects," "anticipates," "estimates," "intends," "plans," "targets," "projects" and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, failure to obtain sufficient capital resources to fund our development program and operations, results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, including the continued development and approval of anti-inflammatory drug candidates, the effect of any competitive products, our ability to license and protect our intellectual property, our significant payables, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices, pending litigation matters, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our annual report on Form 10-K for the fiscal year ended December 31, 2014 filed on March 12, 2015. We undertake no duty to update any forward-looking statement or any information contained in this press release or in other public disclosures at any time.


Investor Contact:
PCG Advisory Group 
Stephanie Prince

Media Contact:
PCG Advisory Group
Sean Leous
646 863 8998

Company Contact:
Ted Jenkins
Corporate Strategy & Development
Rock Creek Pharmaceuticals

Logo -

SOURCE Rock Creek Pharmaceuticals, Inc.